Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5201794
Max Phase: Preclinical
Molecular Formula: C45H45F3N10O8
Molecular Weight: 910.91
Associated Items:
ID: ALA5201794
Max Phase: Preclinical
Molecular Formula: C45H45F3N10O8
Molecular Weight: 910.91
Associated Items:
Canonical SMILES: C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(=O)CCCCCC(=O)Nc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)cc3OC)ncc2C(F)(F)F)c1
Standard InChI: InChI=1S/C45H45F3N10O8/c1-3-35(59)50-26-9-7-10-27(23-26)51-40-30(45(46,47)48)25-49-44(55-40)53-31-16-15-28(24-34(31)66-2)56-19-21-57(22-20-56)38(62)14-6-4-5-13-36(60)52-32-12-8-11-29-39(32)43(65)58(42(29)64)33-17-18-37(61)54-41(33)63/h3,7-12,15-16,23-25,33H,1,4-6,13-14,17-22H2,2H3,(H,50,59)(H,52,60)(H,54,61,63)(H2,49,51,53,55)
Standard InChI Key: KJJWOVIQRJNQJI-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 910.91 | Molecular Weight (Monoisotopic): 910.3374 | AlogP: 5.75 | #Rotatable Bonds: 16 |
Polar Surface Area: 224.37 | Molecular Species: NEUTRAL | HBA: 13 | HBD: 5 |
#RO5 Violations: 3 | HBA (Lipinski): 18 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.57 | CX Basic pKa: 4.34 | CX LogP: 5.38 | CX LogD: 5.38 |
Aromatic Rings: 4 | Heavy Atoms: 66 | QED Weighted: 0.05 | Np Likeness Score: -1.06 |
1. Li Q, Guo Q, Wang S, Wan S, Li Z, Zhang J, Wu X.. (2022) Design and synthesis of proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686., 238 [PMID:35594654] [10.1016/j.ejmech.2022.114455] |
Source(1):